GUJTHEMGujarat Themis Biosyn Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 2.0 this quarter.
Momentum from moving averages, Supertrend and RSI.
8 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
8 found · risk severe
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹50 Cr | ₹-14 Cr | -10.92% | -27.72% | ₹-1.19 | -0.3x |
| Q1 FY2027 | ₹44 Cr | ₹11 Cr | 38.41% | 25.28% | ₹1.02 | 9.5x |
| Q4 FY2026 | ₹44 Cr | ₹11 Cr | 34.64% | 24.62% | ₹1.00 | 8.5x |
| Q3 FY2026 | ₹43 Cr | ₹12 Cr | 40.15% | 28.74% | ₹1.14 | 18.6x |
| Q2 FY2026 | ₹42 Cr | ₹14 Cr | 42.47% | 33.68% | ₹1.31 | Negligible |
| Q1 FY2026 | ₹36 Cr | ₹9 Cr | 33.15% | 25.26% | ₹0.83 | Negligible |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.